Invasive Carcinoma — Research

Invasive Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	8,800	`("Invasive Carcinoma"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	1,872	`("Invasive Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	456	`("Invasive Carcinoma"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (75)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–50 of 75 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed
Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed
Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.